Marc Navre
Takeda Pharmaceutical Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marc Navre.
Bioorganic & Medicinal Chemistry Letters | 2010
Jerome C. Bressi; Andy Jennings; Robert J. Skene; Yiqin Wu; Robert Melkus; Ron de Jong; Shawn O’Connell; Charles E. Grimshaw; Marc Navre; Anthony R. Gangloff
A series of N-(2-amino-5-substituted phenyl)benzamides (3-21) were designed, synthesized and evaluated for their inhibition of HDAC2 and their cytotoxicity in HCT116 cancer cells. Multiple compounds from this series demonstrated time-dependent binding kinetics that is rationalized using a co-complex crystal structure of HDAC2 and N-(4-aminobiphenyl-3-yl)benzamide (6).
Journal of Medicinal Chemistry | 2011
Zhiyuan Zhang; Michael B. Wallace; Jun Feng; Jeffrey A. Stafford; Robert J. Skene; Lihong Shi; Bumsup Lee; Kathleen Aertgeerts; Andy Jennings; Rongda Xu; Daniel B. Kassel; Stephen W. Kaldor; Marc Navre; David R. Webb; Stephen L. Gwaltney
The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.
Bioorganic & Medicinal Chemistry Letters | 2010
Jerome C. Bressi; Ron de Jong; Yiqin Wu; Andy Jennings; Jason W. Brown; Shawn O’Connell; Leslie W. Tari; Robert J. Skene; Phong H. Vu; Marc Navre; Xiaodong Cao; Anthony R. Gangloff
A series of N-hydroxy-3-[3-(1-substituted-1H-benzoimidazol-2-yl)-phenyl]-acrylamides (5a-5ab) and N-hydroxy-3-[3-(1,4,5-trisubstituted-1H-imidazol-2-yl)-phenyl]-acrylamides (12a-s) were designed, synthesized, and found to be nanomolar inhibitors of human histone deacetylases. Multiple compounds bearing an N1-piperidine demonstrate EC(50)s of 20-100 nM in human A549, HL60, and PC3 cells, in vitro and in vivo hyperacetylation of histones H3 and H4, and induction of p21(waf). Compound 5x displays efficacy in human tumor xenograft models.
Bioorganic & Medicinal Chemistry Letters | 1998
Jeremy I. Levin; John F. DiJoseph; Loran M. Killar; Michele A. Sharr; Jerauld S. Skotnicki; Dinesh V. Patel; Xiao-Yi Xiao; Lihong Shi; Marc Navre; David A. Campbell
A series of succinyl based mercaptoketones and diastereomeric mercaptoalcohols were prepared and evaluated in vitro as inhibitors of the matrix metalloproteinases collagenase-1 (MMP-1), stromelysin (MMP-3), and gelatinase-B (MMP-9).
Bioorganic & Medicinal Chemistry Letters | 1998
David Alan Campbell; Xiao-Yi Xiao; David Harris; Satoru Ida; Reza Mortezaei; Khehyong Ngu; Lihong Shi; David Tien; Yongwen Wang; Marc Navre; Dinesh V. Patel; Michele A. Sharr; John F. DiJoseph; Loran M. Killar; Christina Louise Leone; Jeremy I. Levin; Jerauld S. Skotnicki
Abstract A novel series of matrix metalloproteinase (MMP) inhibitors is described. Incorporation of a terminal α-mercaptoketone or α-mercaptoalcohol in the zinc binding domain of a series of inhibitors led to compounds exhibiting low nanomolar activity against collagenase-1 (MMP-1), stromelysin (MMP-3), and gelatinase-B (MMP-9).
Journal of Medicinal Chemistry | 2018
Tao Chen; Nicholas Reich; Noah Bell; Patricia D. Finn; David Rodríguez; Jill Kohler; Kenji Kozuka; Limin He; Andrew Spencer; Dominique Charmot; Marc Navre; Christopher Carreras; Samantha Koo-McCoy; Jocelyn Tabora; Jeremy S. Caldwell; Jeffrey W. Jacobs; Jason G. Lewis
Bile acid signaling and metabolism in the gastrointestinal tract have wide-ranging influences on systemic disease. G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) is one of the major effectors in bile acid sensing, with demonstrated influence on metabolic, inflammatory, and proliferative processes. The pharmacologic utility of TGR5 agonists has been limited by systemic target-related effects such as excessive gallbladder filling and blockade of gallbladder emptying. Gut-restricted TGR5 agonists, however, have the potential to avoid these side effects and consequently be developed into drugs with acceptable safety profiles. We describe the discovery and optimization of a series of gut-restricted TGR5 agonists that elicit a potent response in mice, with minimal gallbladder-related effects. The series includes 12 (TGR5 EC50: human, 143 nM; mouse, 1.2 nM), a compound with minimal systemic availability that may have therapeutic value to patients with type 2 diabetes mellitus, nonalcoholic steatohepatitis, or inflammatory bowel disease.
Structure | 2004
John R. Somoza; Robert J. Skene; Bradley A. Katz; Clifford D. Mol; Joseph D. Ho; Andy Jennings; Christine Luong; Andrew S. Arvai; Joseph J. Buggy; Ellen Chi; Jie Tang; Bi-Ching Sang; Erik Verner; Robert Wynands; Ellen M. Leahy; Douglas R. Dougan; Gyorgy Snell; Marc Navre; Mark W. Knuth; Ronald V. Swanson; Duncan E. McRee; Leslie W. Tari
Journal of Medicinal Chemistry | 2007
Jun Feng; Zhiyuan Zhang; Michael B. Wallace; Jeffrey A. Stafford; Stephen W. Kaldor; Daniel B. Kassel; Marc Navre; Lihong Shi; Robert J. Skene; Tomoko Asakawa; Koji Takeuchi; Rongda Xu; David R. Webb; Stephen L. Gwaltney
Biochemical and Biophysical Research Communications | 2006
Hua Zou; Yiqin Wu; Marc Navre; Bi-Ching Sang
Journal of Medicinal Chemistry | 1999
Anna Katrin Szardenings; Valery V. Antonenko; David Alan Campbell; Nuria DeFrancisco; Satoru Ida; Lihong Shi; Nikolai Sharkov; David Tien; Yongwen Wang; Marc Navre